Pyrimidine A2B selective antagonist compounds, their synthesis and use

US7501407B2 · kind B2 · utility

Assignee

• OSI Pharmaceuticals, LLC · US

Inventors

• Arlindo L. Castelhano · Haverstraw, US
• Bryan McKibben · White Plains, US
• Arno G. Steinig · East Northport, US
• Eric W. Collington · Knebworth, GB

Key dates

• Filing date: Nov 18, 2004
• Grant date: Mar 10, 2009
• Expiry date: Nov 18, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject invention provides compounds having the structure:wherein R1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R2 and R3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R3 is oxygen; R4 and R5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R4NR5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms;